Trimethyllysine, vascular risk factors and outcome in acute ischemic stroke (MARK-STROKE)

Standard

Trimethyllysine, vascular risk factors and outcome in acute ischemic stroke (MARK-STROKE). / Schwedhelm, Edzard; von Lucadou, Mirjam; Peine, Sven; Lezius, Susanne; Thomalla, Götz; Böger, Rainer; Gerloff, Christian; Choe, Chi-Un.

in: AMINO ACIDS, Jahrgang 53, Nr. 4, 04.2021, S. 555-561.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsätzeForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{ed8c3a9fbc2d40e3abc609e951818f09,
title = "Trimethyllysine, vascular risk factors and outcome in acute ischemic stroke (MARK-STROKE)",
abstract = "Trimethyllysine (TML) is involved in the generation of the pro-atherogenic metabolite trimethylamine-N-oxide (TMAO) by gut microbiota. In clinical studies, elevated TML levels predicted major adverse cardiovascular events (MACE) in patients with acute or stable coronary artery disease (CAD). In contrast to cardiovascular patients, the role of TML in patients with acute cerebral ischemia is unknown. Here, we evaluated circulating TML levels in 374 stroke patients from the prospective biomarkers in stroke (MARK-STROKE) study. Compared with 167 matched healthy controls, acute ischemic stroke patients had lower median TML plasma concentrations, i.e. 0.71 vs. 0.47 µmol/L (p < 0.001) and this difference persisted after adjusting for age and sex. TML plasma concentrations were associated with age, serum creatinine, glucose, cholesterol and lysine. Patients with prevalent arterial hypertension, atrial fibrillation or a history of myocardial infarction had increased TML levels, but this observation was not independent of age, sex and GFR. In 274 patients, follow-up data were available. During a median follow-up of 284 [25th-75th percentile: 198, 431] days, TML was not associated with incident MACE (stroke, myocardial infarction, death). In summary, our data suggests a different role of TML in acute ischemic stroke compared with CAD patients.",
author = "Edzard Schwedhelm and {von Lucadou}, Mirjam and Sven Peine and Susanne Lezius and G{\"o}tz Thomalla and Rainer B{\"o}ger and Christian Gerloff and Chi-Un Choe",
year = "2021",
month = apr,
doi = "10.1007/s00726-021-02969-x",
language = "English",
volume = "53",
pages = "555--561",
journal = "AMINO ACIDS",
issn = "0939-4451",
publisher = "Springer Wien",
number = "4",

}

RIS

TY - JOUR

T1 - Trimethyllysine, vascular risk factors and outcome in acute ischemic stroke (MARK-STROKE)

AU - Schwedhelm, Edzard

AU - von Lucadou, Mirjam

AU - Peine, Sven

AU - Lezius, Susanne

AU - Thomalla, Götz

AU - Böger, Rainer

AU - Gerloff, Christian

AU - Choe, Chi-Un

PY - 2021/4

Y1 - 2021/4

N2 - Trimethyllysine (TML) is involved in the generation of the pro-atherogenic metabolite trimethylamine-N-oxide (TMAO) by gut microbiota. In clinical studies, elevated TML levels predicted major adverse cardiovascular events (MACE) in patients with acute or stable coronary artery disease (CAD). In contrast to cardiovascular patients, the role of TML in patients with acute cerebral ischemia is unknown. Here, we evaluated circulating TML levels in 374 stroke patients from the prospective biomarkers in stroke (MARK-STROKE) study. Compared with 167 matched healthy controls, acute ischemic stroke patients had lower median TML plasma concentrations, i.e. 0.71 vs. 0.47 µmol/L (p < 0.001) and this difference persisted after adjusting for age and sex. TML plasma concentrations were associated with age, serum creatinine, glucose, cholesterol and lysine. Patients with prevalent arterial hypertension, atrial fibrillation or a history of myocardial infarction had increased TML levels, but this observation was not independent of age, sex and GFR. In 274 patients, follow-up data were available. During a median follow-up of 284 [25th-75th percentile: 198, 431] days, TML was not associated with incident MACE (stroke, myocardial infarction, death). In summary, our data suggests a different role of TML in acute ischemic stroke compared with CAD patients.

AB - Trimethyllysine (TML) is involved in the generation of the pro-atherogenic metabolite trimethylamine-N-oxide (TMAO) by gut microbiota. In clinical studies, elevated TML levels predicted major adverse cardiovascular events (MACE) in patients with acute or stable coronary artery disease (CAD). In contrast to cardiovascular patients, the role of TML in patients with acute cerebral ischemia is unknown. Here, we evaluated circulating TML levels in 374 stroke patients from the prospective biomarkers in stroke (MARK-STROKE) study. Compared with 167 matched healthy controls, acute ischemic stroke patients had lower median TML plasma concentrations, i.e. 0.71 vs. 0.47 µmol/L (p < 0.001) and this difference persisted after adjusting for age and sex. TML plasma concentrations were associated with age, serum creatinine, glucose, cholesterol and lysine. Patients with prevalent arterial hypertension, atrial fibrillation or a history of myocardial infarction had increased TML levels, but this observation was not independent of age, sex and GFR. In 274 patients, follow-up data were available. During a median follow-up of 284 [25th-75th percentile: 198, 431] days, TML was not associated with incident MACE (stroke, myocardial infarction, death). In summary, our data suggests a different role of TML in acute ischemic stroke compared with CAD patients.

U2 - 10.1007/s00726-021-02969-x

DO - 10.1007/s00726-021-02969-x

M3 - SCORING: Journal articles

C2 - 33788002

VL - 53

SP - 555

EP - 561

JO - AMINO ACIDS

JF - AMINO ACIDS

SN - 0939-4451

IS - 4

ER -